Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. - Wikidata - awgldk - TriplyDB

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

http://www.wikidata.org/entity/Q38990471

about

Hepatitis C genotype 4: The past, present, and future Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6 Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy Hepatitis C: a clinical review Predictors of sustained virologic response in hepatitis C genotype 4 : beyond the usual suspects Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.New antiviral therapies for chronic hepatitis C The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study.European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.Effects of Nigella sativa on outcome of hepatitis C in Egypt.Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.Chronic hepatitis C virus infection: genotyping and its clinical role.Improving outcome in patients with hepatitis C virus genotype 4.Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.A Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients.Optimizing the treatment of chronic viral hepatitis C.Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.Hepatitis C treatment: trial by design.Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-α/ribavirin therapy in chronic hepatitis C genotype 4 patients.Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting.

P2860

Q26775815-B04BE8E2-6B9C-4660-968E-D77CEDFED695 Q26828972-2CF91BCB-1BA0-4CAC-B5BB-E3091DA03135 Q26991791-123EF937-FD59-4CB0-91F6-30FAE42F21B9 Q27489040-6FD06593-6349-460D-8ACB-6ADA6052D439 Q27490788-86EE76B8-06AB-4843-A60A-E14E27421832 Q27490865-969B2D3D-01A7-4AA9-B379-6EA7048CEEB5 Q27490866-B3298F37-949D-49EE-A9BD-976941514515 Q27490902-6E10EE16-842D-46B2-8324-5A01885C673F Q33918559-A9507290-F793-4441-B090-E7B04A290490 Q34130399-07EA26E0-56A5-4633-B425-8BC1D6CD443B Q34996891-16AE57EC-DA59-4B58-8DD7-403FC7663593 Q35101026-5679D194-22B3-4E18-9870-E88530A7101D Q35714986-8906FF19-2035-4A55-A80F-5F153585F043 Q36821645-0BCF9FF4-9E13-42B3-B85E-B434FBEC5504 Q36841724-025DF258-D1C3-4A33-AD9D-0684B00AAD0F Q36895749-973424DA-0993-4EB7-A573-F4D7B24542D4 Q36953707-EF023A70-882B-4637-9487-91E084D78CEF Q37243555-F3E77B0F-2FA4-44DC-BF72-A728EF383830 Q37424353-84A1937D-6DE4-405D-853C-16F446DFC872 Q37636095-316DD2EA-FA4C-4BA5-9F0B-4896522EB762 Q38164114-E29C2E0E-9DC2-40C1-BBC9-D5EB86217C32 Q38224436-F689B25D-E59E-42CE-9CA0-217B08108C32 Q40712261-00E92CC2-4C4F-4B0B-A292-CE751D064E99 Q42382462-F6E1E90E-4002-4CE3-96BD-12115B0959B1 Q43104890-1D02C5EB-AB6F-4792-B900-A5B5437EC5CA Q46913441-065C4DB5-B7B4-48A5-B154-E23B2C930BFE Q55263598-5C097724-C306-4A7B-9D15-E4B5A47D5361

P2860

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

http://www.wikidata.org/entity/Q38990471

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Response of hepatitis C genoty ...... n-randomized controlled study.

@en

type

label

Response of hepatitis C genoty ...... n-randomized controlled study.

@en

prefLabel

Response of hepatitis C genoty ...... n-randomized controlled study.

@en

P1433

Q38990471-9659CFB4-AA59-4992-A3A2-4765AA00EF7C

P1476

Q38990471-52EB5969-CA71-451B-A697-2C89A52C35D6

P2093

Q38990471-290ABC27-E382-487D-9C7F-D7B2E17C7B1E

Q38990471-6607BC1A-5605-4173-897F-A2955911275D

Q38990471-7CD3094D-CD15-42E8-A501-B757280D203E

Q38990471-819EFEE4-B8FF-4EB2-A542-F52BD96BFEF8

Q38990471-9E43D4B9-5224-44C8-AABD-2B69C902F129

Q38990471-AE629887-9CDC-4ACA-A448-49C1ACD35D37

Q38990471-B3C275F6-C2B0-4395-A367-0635D70287BA

Q38990471-E7D855ED-2049-4778-A543-A77A53A12420

Q38990471-F0C4AB8B-29A5-4151-B12D-0E963A77E73B

P2860

Q38990471-1759AB9A-B62F-4CCC-95B8-432A04AC8FF7

Q38990471-1C0EE2D1-D148-40BB-B90A-B331644CC751

Q38990471-360E7491-5B7C-4F6D-A509-2ABB74D84051

Q38990471-3E3B01B1-A3FC-47A0-A638-6B6A1196EF6D

Q38990471-406E122F-279E-40AE-965A-EAB86D0DED36

Q38990471-4811F6D9-D330-41DD-8EC7-2241FA179F51

Q38990471-74B28E09-8B2C-4502-BDED-32D58B306A32

Q38990471-753AA476-9192-4378-9427-AA1F672ADA4C

Q38990471-8DB39F72-4ADE-4893-A194-F84D77C23306

Q38990471-AFF0B391-8FCE-4059-9D3E-E3C1C2FB39F2

P304

Q38990471-D2EA47D8-EBAB-4C73-8042-20DB0138F81F

P31

Q38990471-B0FDEAF4-738F-4710-8576-F54C279E4A95

P356

Q38990471-5E9B3750-0578-4FF9-A0DE-00C1E27E036D

P407

Q38990471-0BB96997-6B91-41E5-9141-BF4E384951D7

P433

Q38990471-80913837-8F89-4D6A-B4EB-A1C6FB3986EC

P478

Q38990471-2CF2CA25-24F1-440E-98DE-63153B416344

P577

Q38990471-BA36BFCC-C264-4C0E-A654-E75C66AB29C2

P698

Q38990471-25AB8320-B8E7-4A11-AD50-1A1B89318F15

P356

J.1572-0241.2005.00253.X

P1433

The American Journal of Gastroenterology

P1476

Response of hepatitis C genoty ...... n-randomized controlled study.

@en

P2093

Abdel-Rahman El-Zayadi

http://www.w3.org/2001/XMLSchema#string

Adham El-Nakeeb

http://www.w3.org/2001/XMLSchema#string

Ahmed El-Tawil

http://www.w3.org/2001/XMLSchema#string

Ahmed Saied

http://www.w3.org/2001/XMLSchema#string

Eman M F Barakat

http://www.w3.org/2001/XMLSchema#string

Hanaa M Badran

http://www.w3.org/2001/XMLSchema#string

Hassan Hamdy

http://www.w3.org/2001/XMLSchema#string

Mohy Attia

http://www.w3.org/2001/XMLSchema#string

Osaima Selim

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Histological grading and staging of chronic hepatitis

Optimal therapy of hepatitis C.

Predictors of response to therapy for chronic hepatitis C.

Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity.

Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience.

Hepatitis C virus genotyping versus serotyping in Egyptian patients.

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

P304

2447-2452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2005.00253.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16279899

http://www.w3.org/2001/XMLSchema#string